China SXT Pharmaceuticals Inc Cash Flow Conversion Efficiency
China SXT Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, China SXT Pharmaceuticals Inc (SXTC) has a cash flow conversion efficiency ratio of -0.076x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.26 Million) by net assets ($29.71 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of China SXT Pharmaceuticals Inc (2016–2026)
Cash flow conversion efficiency of China SXT Pharmaceuticals Inc from 2016 to 2026. This chart illustrates how China SXT Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View SXTC stock price for real-time trading data and today's change.
China SXT Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
China SXT Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
China SXT Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of China SXT Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see China SXT Pharmaceuticals Inc (SXTC) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Upsellon Brands Holdings Ltd
TA:CHR
|
0.180x |
|
Steakholder Foods Ltd
NASDAQ:STKH
|
-0.728x |
|
SECITS Holding AB (publ)
ST:SECI
|
0.666x |
|
Purple Biotech Ltd
TA:KTOV
|
-0.041x |
|
Time Out Group plc
LSE:TMO
|
-0.052x |
|
Bessor Minerals Inc
V:BST
|
0.063x |
|
iQ International AG
F:IQL
|
0.040x |
|
CELLECTAR NEW22 DL-00001
F:NV4
|
N/A |
Annual Cash Flow Conversion Efficiency for China SXT Pharmaceuticals Inc (2016–2026)
The table below shows the annual cash flow conversion efficiency of China SXT Pharmaceuticals Inc from 2016 to 2026. Review how much free cash does China SXT Pharmaceuticals Inc generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-03-31 | $29.71 Million | $-4.02 Million | -0.135x | +10.97% |
| 2025-03-31 | $15.44 Million | $-2.35 Million | -0.152x | -9.75% |
| 2024-03-31 | $13.93 Million | $-1.93 Million | -0.138x | -2417.87% |
| 2023-03-31 | $14.69 Million | $-80.76K | -0.005x | +96.20% |
| 2022-03-31 | $16.42 Million | $-2.37 Million | -0.145x | -75.27% |
| 2021-03-31 | $15.96 Million | $-1.32 Million | -0.082x | -183.00% |
| 2020-03-31 | $9.40 Million | $934.25K | 0.099x | +361.48% |
| 2019-03-31 | $11.11 Million | $239.19K | 0.022x | -96.32% |
| 2018-03-31 | $3.29 Million | $1.92 Million | 0.584x | +269.46% |
| 2017-03-31 | $1.85 Million | $293.04K | 0.158x | -35.61% |
| 2016-03-31 | $742.77K | $182.47K | 0.246x | -- |
About China SXT Pharmaceuticals Inc
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers Advanced TCMP, including Directly-Oral-TCMP, and After-Soaking-Oral TCMP; Fine TCMP and Regular TCMP products; and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo,… Read more